At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 3,069 enrolled
Drug / intervention
Ginkgo biloba +1 moredrug
Likely dose
Ginkgo biloba 120 mg orally twice dailyAI-extracted
Key inclusion· 4
- ✓Cognitively normal (non-demented) at baseline
- ✓Willing to commit to seven-year follow-up
- ✓English-speaking
- ✓Has a willing informant with frequent contact
Key exclusion· 10
- ✕Currently on anticoagulant therapy
- ✕Cancer diagnosed and treated in the past two years (except skin cancer)
- ✕Class III–IV congestive heart failure
- ✕Currently treated with psychopharmacological drugs for depression
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ginkgo Biloba Prevention Trial in Older Individuals
National Center for Complementary and Integrative Health (NCCIH)·interventional·Posted Feb 5, 2001·Updated Mar 14, 2013
In Brief
A Phase 3 clinical trial evaluating Ginkgo biloba and Placebo for Dementia and Alzheimer's Disease. Completed, enrolled 3,069 participants across 5 sites.
Detailed Summary
This study will determine the effect of 240mg/day Ginkgo biloba in decreasing the incidence of dementia and specifically Alzheimer's disease (AD), slowing cognitive decline and functional disability, reducing incidence of cardiovascular disease, and decreasing total mortality.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDementia, Alzheimer's Disease
CountriesUnited States
Timeline
Phase 3CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2000
First PostedFeb 2001
Primary CompletionApr 2008
Study CompletionJul 2011
TodayJul 2026
First PostedFeb 5, 2001
Enrollment StartOct 1, 2000
Primary CompletionApr 1, 2008
Study CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 25.4 years ago
Interventions
Ginkgo bilobadrug
120mg twice a day
Placebodrug
One pill twice daily